Healthcare
Sight Sciences, Inc.(SGHT)
Live Price
Offline$5.28
+5.39% today
1Y Change
+15.44%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $240.00M
- Revenue Growth
- -3.1%
- EPS Growth
- +28.2%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sight Sciences, Inc. (SGHT) is a Healthcare stock with a market cap of $240.00M and listed on NASDAQ. The stock last traded around $5.28 and up 15.4% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -3.1%, EPS growth of +28.2%, a dividend yield of 0.0%. What stands out right now is revenue -3.1%, EPS +28.2%, free cash flow -31.6% with operating margin -48.0% and ROIC -35.4%. Valuation is more restrained than many high-expectation growth names at price/sales 3.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SGHT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-3.1% vs +7.6% peer median
Operating Margin
Below sector median
-48.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 6, 2026 with an EPS surprise of +15.8% and a revenue surprise of +6.7%.
The operating picture looks softer than before
Revenue is at -3.1% and EPS is at +28.2%, with operating margin around -48.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | +15.8% | +23.0% | +14.0% | +7.0% |
2026 Mar 4, 2026 | +46.7% | -26.8% | -31.6% | -32.3% |
2025 Nov 6, 2025 | +38.5% | +16.4% | +41.0% | +61.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGHT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SGHT Max Drawdown
-61.88%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SGHT and SPY.
Company Overview
Sight Sciences, Inc.
NASDAQ Global Select
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
- Leadership
- Paul Badawi
- IPO Date
- Jul 15, 2021
- Employees
- 216
- Street Address
- 4040 Campbell Avenue
- Mailing
- Menlo Park, CA, 94025
- Region
- Menlo Park, CA, US
- Reporting Currency
- USD
- Investor Line
- 877 266 1144
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.1
- Price/Book
- 3.7
Growth
- Revenue
- -3.1%
- EPS
- +28.2%
- Free Cash Flow
- -31.6%
Profitability
- Gross Margin
- 86.2%
- Operating Margin
- -48.0%
- Net Margin
- -49.7%
- ROE
- -55.7%
- ROIC
- -35.4%
Balance Sheet
- Debt/Equity
- 0.64
- Current Ratio
- 10.22
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.